TY - JOUR
T1 - Tetramer formation of a variant type human transthyretin (prealbumin) produced by Escherichia coli expression system
AU - Furuya, Hirokazu
AU - Nakazato, Masamitsu
AU - Saraiva, Maria Joao Mascarenhas
AU - Costa, Pedro P.
AU - Sasaki, Hiroyuki
AU - Matsuo, Hisayuki
AU - Goto, Ikuo
AU - Sakaki, Yoshiyuki
N1 - Funding Information:
We are grateful to Dr. Satoshi Inouye, Chisso Cooperation(Japan) for site-directed mutagenesis. This work is supported by grants from JNICT(Portugal) (#87440) and the US National Institutes of Health(#R01NS25190) to M.J.M Saraiva and from The Kato Memorial Trust for Nambyo Research to Y. Sakaki.
PY - 1989/9/15
Y1 - 1989/9/15
N2 - A variant of human transthyretin(TTR, prealbumin) with methionine for valine substitution at position 30 is a major component of amyloid fibrils found in patients of familial amyloidotic polyneuropathy(FAP) type I, an autosomal dominant genetic disease. But the molecular nature of the variant TTR has been obscure, because most of plasma TTR from FAP patients is a mixture of variant and wild type TTR and no pure preparation of the variant has been available. For this reason, we constructed a system in which the variant type TTR was efficiently synthesized. In this system, the recombinant variant TTR was first synthesized as a fusion protein with E. coli outer membrane protein A (ompA) signal peptide, processed to eliminate the signal peptide and finally secreted to the culture medium. The final concentration of the recombinant variant TTR in the medium was about 5 mg/l. SDS polyacrylamide gel electrophoresis and gel filtration analysis suggested that the recombinant variant TTR can form tetramer as seen for native one. Purification of the protein was accomplished by only two steps of chromatography.
AB - A variant of human transthyretin(TTR, prealbumin) with methionine for valine substitution at position 30 is a major component of amyloid fibrils found in patients of familial amyloidotic polyneuropathy(FAP) type I, an autosomal dominant genetic disease. But the molecular nature of the variant TTR has been obscure, because most of plasma TTR from FAP patients is a mixture of variant and wild type TTR and no pure preparation of the variant has been available. For this reason, we constructed a system in which the variant type TTR was efficiently synthesized. In this system, the recombinant variant TTR was first synthesized as a fusion protein with E. coli outer membrane protein A (ompA) signal peptide, processed to eliminate the signal peptide and finally secreted to the culture medium. The final concentration of the recombinant variant TTR in the medium was about 5 mg/l. SDS polyacrylamide gel electrophoresis and gel filtration analysis suggested that the recombinant variant TTR can form tetramer as seen for native one. Purification of the protein was accomplished by only two steps of chromatography.
UR - http://www.scopus.com/inward/record.url?scp=0024455085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024455085&partnerID=8YFLogxK
U2 - 10.1016/0006-291X(89)92300-0
DO - 10.1016/0006-291X(89)92300-0
M3 - Article
C2 - 2675831
AN - SCOPUS:0024455085
SN - 0006-291X
VL - 163
SP - 851
EP - 859
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 2
ER -